Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:06:51.137Z.
Calculation as of: 2026-10-06T15:06:51.137Z.
Quote observation: 2026-10-06T15:05:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 325841a12d79c3b22e4488d0564adef7d4bfa7ba78e5cc1d4c3dcb4b1cd6f762
PE RATIO
N/A
Market Cap
$1.45M
PE Ratio
N/A
TTM Avg
21295.08
3Y Avg
21295.08
5Y Avg
21295.08
Market Cap
$1.47M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genprex, Inc. (GNPX) | $1.35M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.39M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | N/A | 21295.08 | 21295.08 | 21295.08 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.47M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.47M | N/A | 47.01 | 47.01 | 34.74 |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.68
Forward EPS (Est.)
$-1265.00
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
